ANRO — Alto Neuroscience, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1999480 ·
Last close
$24.03
Market Cap
$942.99M
52W High
$37.48
52W Low
$5.22
ADV30
566,195
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -29,129,000 | -27,638,000 | 254,066,000 | 243,733,000 | 34,817,000 |
| Mar 2026 | 0 | — | -27,138,000 | -26,237,000 | 276,259,000 | 263,762,000 | 32,890,000 |
| Dec 2025 | 0 | — | -17,055,000 | -16,182,000 | 184,689,000 | 176,484,000 | 33,547,000 |
| Sep 2025 | 0 | — | -14,951,000 | -14,181,000 | 147,006,000 | 137,816,000 | 35,449,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,304,000
Investing CF
$-556,000
Financing CF
$165,892,000
CapEx
$-1,086,000
Dividends Paid
—
Buybacks
$-4,875,000
EPS Diluted TTM
$-2.53
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-227,871,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-71,890,000
Pretax Income TTM
$-74,306,000
Interest Exp TTM
$2,416,000
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -66,364,000 | -63,238,000 | 184,689,000 | 33,547,000 | 151,142,000 | -51,769,000 |
| Dec 2024 | 0 | -68,610,000 | -61,431,000 | 177,542,000 | 26,082,000 | 151,460,000 | -47,424,000 |
| Dec 2023 | 0 | -37,809,000 | -36,305,000 | 86,628,000 | 158,300,000 | -71,672,000 | -33,448,000 |
| Dec 2022 | 0 | -27,455,000 | -27,710,000 | 50,854,000 | 89,260,000 | -38,406,000 | -20,394,000 |
TTM Snapshot
Revenues TTM
$6,337,000
NetIncome TTM
$-74,306,000
OpCashFlow TTM
—
Assets (Latest)
$276,259,000
Forward EPS
$-3.29
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $24.03 · call volume: 28 · put volume: 185
Expected Move to 2027-01-15:
±$6.23
(25.93%) —
implied range
$17.80 –
$30.26
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KURA | Kura Oncology, Inc. | $935.87M | $10.52 | — |
| AKTS | Aktis Oncology, Inc. | $953.47M | $17.74 | — |
| SPTX | Seaport Therapeutics, Inc. | $958.73M | $17.91 | — |
| ANL | Adlai Nortye Group Ltd. | $910.97M | $15.51 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $910.08M | $48.72 | — |
News headlines (Yahoo Finance, 1h cache)
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
2026-09-09 12:03 · Yahoo
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
2026-08-27 20:05 · Yahoo
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
2026-08-16 20:07 · Yahoo
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?
2026-08-16 08:08 · Yahoo
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans
2026-08-16 03:16 · Yahoo
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
2026-07-13 11:47 · Yahoo
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?
2026-07-02 19:58 · Yahoo
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
2026-06-15 12:03 · Yahoo
Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data
2026-04-02 18:36 · Yahoo
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss
2026-04-02 20:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.